Prof. Dr. Raja Atreya

Professur für Translationale Immunforschung bei chronisch entzündlichen Darmerkrankungen

Integrin αVβ6: Autoantigen and Driver of Epithelial Remodeling in Colon and Bile Ducts in Primary Sclerosing Cholangitis and Inflammatory Bowel Disease. (2025) Roth D, Düll M, Horst LJ, Lindemann A, Malzer X, Koop K, Zundler S, et al. Journal article Engineering Therapeutic Regulatory T Cells to Overexpress G Protein-Coupled Receptor 15 Improves Functional Fitness for In Vivo Gut Homing (2025) Müller T, Liu L, Wiesinger M, Atreya I, Atreya R, Bacher P, Becker C, et al. Journal article, Letter Epithelial OPA1 links mitochondrial fusion to inflammatory bowel disease (2025) Bao L, Yu Y, Gonzalez Acera M, Patankar J, Gießl A, Sturm G, Kühl AA, et al. Journal article Therapie des schweren Schubs bei Morbus Crohn und Colitis ulcerosa (2025) Stallmach A, Stallhofer J, Schmidt C, Atreya R, Grunert PC Journal article MRI Volumetric Changes in Perianal Fistulizing Crohn's Disease: Moving Toward a Novel Outcome Measure for Therapeutic Response (2025) Atreya R, Neurath M Journal article, Editorial Paucity of viral infection symptoms in patients with immune-mediated inflammatory diseases. (2025) Yalcin-Mutlu M, Kleyer A, Krönke G, Fagni F, Temiz SA, Meder C, Dietrich P, et al. Journal article Clinical Pharmacist Counselling Improves Long-term Medication Safety and Patient-reported Outcomes in Anti-TNF-treated Patients With Inflammatory Bowel Diseases: The Prospective, Randomized AdPhaNCED Trial. (2025) Plechschmidt J, Fietkau K, Hepp T, Dietrich P, Fischer S, Krebs S, Neurath M, et al. Journal article Add-on multiple submucosal injections of the RNA oligonucleotide GUT-1 to anti-TNF antibody treatment in patients with moderate-to-severe ulcerative colitis: an open-label, proof-of concept study (2024) Suzuki K, Sameshima Y, Yokoyama J, Terai S, Yoneyama H, Atreya R, Neurath M, et al. Journal article Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials (2024) Peyrin‐Biroulet L, Arkkila P, Armuzzi A, Danese S, Ferrante M, Jordi Guardiola , Jahnsen J, et al. Journal article Reverse switching from the biosimilar SB2 to the originator infliximab in previously switched patients with inflammatory bowel diseases: results of a prospective long-term cohort study (2024) Fischer S, Donhauser M, Cohnen SE, Fietkau K, Vetter M, Grübel-Liehr M, Dietrich P, et al. Journal article